Bonus Biogroup Stock Performance
| BBIXF Stock | USD 0.08 0.00 0.00% |
Bonus BioGroup holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -241.11, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Bonus BioGroup are expected to decrease by larger amounts. On the other hand, during market turmoil, Bonus BioGroup is expected to outperform it. Use Bonus BioGroup variance, skewness, as well as the relationship between the Skewness and day typical price , to analyze future returns on Bonus BioGroup.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Bonus BioGroup are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Bonus BioGroup reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 16.1 M | |
| Total Cashflows From Investing Activities | -6.2 M |
Bonus |
Bonus BioGroup Relative Risk vs. Return Landscape
If you would invest 2.00 in Bonus BioGroup on October 12, 2025 and sell it today you would earn a total of 6.00 from holding Bonus BioGroup or generate 300.0% return on investment over 90 days. Bonus BioGroup is currently producing 14.3095% returns and takes up 126.7969% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Bonus, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Bonus BioGroup Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bonus BioGroup's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Bonus BioGroup, and traders can use it to determine the average amount a Bonus BioGroup's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1129
| High Returns | Best Equity | BBIXF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Bonus BioGroup is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bonus BioGroup by adding it to a well-diversified portfolio.
Bonus BioGroup Fundamentals Growth
Bonus Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Bonus BioGroup, and Bonus BioGroup fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bonus Pink Sheet performance.
| Return On Equity | -0.55 | |||
| Return On Asset | -0.0636 | |||
| Current Valuation | 48.99 M | |||
| Shares Outstanding | 1.17 B | |||
| Price To Book | 4.05 X | |||
| EBITDA | (88.03 M) | |||
| Debt To Equity | 0.15 % | |||
| Cash Flow From Operations | (39.84 M) | |||
| Total Asset | 104.32 M | |||
About Bonus BioGroup Performance
By analyzing Bonus BioGroup's fundamental ratios, stakeholders can gain valuable insights into Bonus BioGroup's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bonus BioGroup has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bonus BioGroup has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel. Bonus Biogroup is traded on OTC Exchange in the United States.Things to note about Bonus BioGroup performance evaluation
Checking the ongoing alerts about Bonus BioGroup for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Bonus BioGroup help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bonus BioGroup is way too risky over 90 days horizon | |
| Bonus BioGroup has some characteristics of a very speculative penny stock | |
| Bonus BioGroup appears to be risky and price may revert if volatility continues | |
| Bonus BioGroup has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (90.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bonus BioGroup generates negative cash flow from operations | |
| About 50.0% of the company shares are held by company insiders |
- Analyzing Bonus BioGroup's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bonus BioGroup's stock is overvalued or undervalued compared to its peers.
- Examining Bonus BioGroup's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bonus BioGroup's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bonus BioGroup's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bonus BioGroup's pink sheet. These opinions can provide insight into Bonus BioGroup's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bonus Pink Sheet analysis
When running Bonus BioGroup's price analysis, check to measure Bonus BioGroup's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bonus BioGroup is operating at the current time. Most of Bonus BioGroup's value examination focuses on studying past and present price action to predict the probability of Bonus BioGroup's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bonus BioGroup's price. Additionally, you may evaluate how the addition of Bonus BioGroup to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |